The Board of Directors

WHRL was established in 1990 to facilitate interaction between academia and the pharmaceutical industry. A primary aim of WHRL is to co-ordinate contract research as an Efficacy, Verification and Interpretation Service (EVIS). Scientific personnel of the William Harvey Research Institute provide the foundation of experience and expertise to complement drug development for pharmaceutical and biotech companies. WHRL also organises conferences, facilitates PhD fellowships and provides registration and payment management services.

Governed by a diverse and dedicated Board of Directors, the company benefits from the strong leadership of scientific, clinical and industry knowledge. 

Meet our Board Members:

Chris Thiemermann

Prof Christoph Thiemermann, MD PhD FBPhS FRCP FRSB FMedSci

Chairman & Chief Executive

LinkedIn

PubMed

c.thiemermann@qmul.ac.uk 

See profile

Brendan Whittle

Prof Brendan J. Whittle, B.Pharm., Ph.D., D.Sc., HonF.BPhS., HonM.FinPhS

LinkedIn

PubMed

b.j.whittle@qmul.ac.uk

See profile

Magdi Yaqoob

Prof Magdi Yaqoob, MD, FRCP

LinkedIn

PubMed

m.m.yaqoob@qmul.ac.uk 

See profile

Mauro Perretti

Prof Mauro Perretti, PhD

LinkedIn

PubMed

m.perretti@qmul.ac.uk

See profile